Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

[1]  E Wiltshaw,et al.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Rubin,et al.  Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Christian,et al.  Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Andrew Bottomley,et al.  EORTC QLQ-C30 Scoring Manual , 1995 .

[5]  David Machin,et al.  Survival Analysis: A Practical Approach , 1995 .

[6]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, New England Journal of Medicine.

[7]  G. Giaccone,et al.  Clinical pharmacology of carboplatin administered in combination with paclitaxel. , 1997, Seminars in oncology.

[8]  D. Alberts,et al.  Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. , 1998, British Journal of Cancer.

[9]  P. Rose,et al.  Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Buyse,et al.  ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer , 1998, The Lancet.

[11]  M. Piccart,et al.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. , 2000, Journal of the National Cancer Institute.

[12]  F M Muggia,et al.  Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  F. Bray,et al.  Cancer burden in the year 2000. The global picture. , 2001, European journal of cancer.

[14]  V. Torri,et al.  Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  I. Tannock,et al.  Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial , 2002, The Lancet.

[16]  E. Venkatraman,et al.  Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Parmar,et al.  First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence , 2002, British Journal of Cancer.